Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2340/00015555-0330 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Commentary on the "Duration of Oral Antibiotics Administration for Cetuximab-Induced Acneiform Eruption".
Dermatology
July 2022
School of Medicine, Royal College of Surgeons in Ireland - Medical University of Bahrain, Muharraq, Bahrain.
Acneiform eruption is a devastating cutaneous side effect of cetuximab, a monoclonal antibody used to treat a variety of cancers. Despite its effectiveness, many patients avoid or discontinue it after experiencing its dermatological side effects as it negatively impacts their quality of life (QoL). This displays the immense need for multidisciplinary collaboration to prevent and treat cetuximab-induced acneiform eruption (CIAE).
View Article and Find Full Text PDFDuration of Oral Antibiotics Administration for Cetuximab-Induced Acneiform Eruption.
Dermatology
November 2021
Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Background: Acneiform eruption is the most common cutaneous adverse event associated with cetuximab. As it can affect quality of life and adversely affect chemotherapy schedule, additional medical care is required.
Objectives: To investigate the adherence to and the duration of antibiotic administration to treat cetuximab-induced acneiform eruption.
Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.
Cancer Chemother Pharmacol
October 2019
Spitalzentrum Biel, Medizinische Onkologie, Biel, Switzerland.
Purpose: The study aimed to investigate strategies to prevent and treat cetuximab-induced skin reactions and their perceived effectiveness in patients with metastatic colorectal cancer (mCRC) and recurrent/metastatic squamous cell cancer of the head and neck (SCCHN).
Methods: This open-label, prospective observational study was conducted in Switzerland.
Results: A total of 125 patients were included (n = 91 mCRC, n = 34 SCCHN; mean age 63.
Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK.
Front Oncol
December 2018
Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan.
Skin toxicity is a common adverse event during cetuximab (Cmab) treatment. However, few reports have investigated the correlation between skin toxicity and the efficacy of Cmab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We retrospectively reviewed 112 R/M SCCHN patients who received palliative chemotherapy with Cmab.
View Article and Find Full Text PDFSkin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy.
Asian Pac J Cancer Prev
August 2018
Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Japan. Email:
Background: Cetuximab-induced skin disorder is common in colorectal cancer (CRC), and is known to affect prolonged overall survival (OS). Patients with left-sided CRC survive longer than those with right-sided CRC, among those treated with combination cetuximab and chemotherapy. However, no study has evaluated patient prognosis in terms of OS and progression-free survival (PFS) in relation to both tumor location and skin disorder.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!